BioCentury | Nov 8, 2019
Clinical News

Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year

...muscular dystrophy. Roche (SIX:ROG; OTCQX:RHHBY) sent a letter Wednesday to the DMD community, including non-profit Parent Project Muscular Dystrophy...
BioCentury | Sep 4, 2019
Politics & Policy

Former commissioners, patient groups endorse Sharpless as permanent FDA leader

...of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Friends of Cancer Research and Parent Project Muscular Dystrophy...
...next Commissioner.” Steve Usdin, Washington Editor American Association for Cancer Research American Society of Clinical Oncology Friends of Cancer Research Parent Project Muscular Dystrophy Andrew...
BioCentury | Jun 28, 2019
Clinical News

Pfizer planning Phase III for DMD gene therapy, close on Sarepta's heels

...race to the finish line between it and Sarepta. Pfizer Inc. (NYSE:PFE) said at the Parent Project Muscular Dystrophy...
BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

...published natural history data. FibroGen presented the data on the mAb against CTGF at the Parent Project Muscular Dystrophy...
BioCentury | Dec 20, 2018
Politics & Policy

FDA releases next guidance in patient-focused drug development series

...all stakeholders including patient advocacy groups, some of whom have already submitted guidances to FDA. Parent Project Muscular Dystrophy...
...scientific data to represent patient experiences rather than compiled anecdotes (see "Making Patients Partners" ). Allison Johnson FDA Parent Project Muscular Dystrophy Amyloidosis...
BioCentury | Jun 21, 2018
Company News

Sarepta says no to right to try for its DMD therapies

...hope is that it will get approved, and compassionate use won't be necessary," Miller said. Parent Project Muscular Dystrophy...
BioCentury | Feb 24, 2018
Regulation

Herculean task for DMD

...Inc., Summit Therapeutics plc and Wave Life Sciences Ltd. Steering Committee members include CureDuchenne and Parent Project Muscular Dystrophy...
...Calif. Duchenne UK, London, U.K. National Institute for Health and Care Excellence (NICE), London, U.K. Parent Project Muscular Dystrophy...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

...testing 1.1 x 10 14 vg/kg AVXS-101 in SMA type 1 patients. On Jan. 17, Parent Project Muscular Dystrophy...
...Harvard Medical School, Boston, Mass. LogicBio Therapeutics Inc., Cambridge, Mass. Nationwide Children’s Hospital, Columbus, Ohio. Parent Project Muscular Dystrophy...
BioCentury | Jan 4, 2018
Financial News

SomaLogic completes $200M financing round

...meaningful signals about health, disease and aging" (see BioCentury Extra, Jan. 6, 2017) . Mary Romeo iCarbonX Novartis AG Parent Project Muscular Dystrophy SomaLogic...
BioCentury | Dec 23, 2017
Regulation

Prioritizing preferences

...at LUNGevity, told BioCentury after the meeting. Annie Kennedy, SVP for legislation and policy at Parent Project Muscular Dystrophy...
...Brunswick, N.J. Kidney Health Initiative, Washington, D.C. LUNGevity, Chicago, Ill. Milken Institute, Santa Monica, Calif. Parent Project Muscular Dystrophy...
Items per page:
1 - 10 of 49
BioCentury | Nov 8, 2019
Clinical News

Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year

...muscular dystrophy. Roche (SIX:ROG; OTCQX:RHHBY) sent a letter Wednesday to the DMD community, including non-profit Parent Project Muscular Dystrophy...
BioCentury | Sep 4, 2019
Politics & Policy

Former commissioners, patient groups endorse Sharpless as permanent FDA leader

...of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Friends of Cancer Research and Parent Project Muscular Dystrophy...
...next Commissioner.” Steve Usdin, Washington Editor American Association for Cancer Research American Society of Clinical Oncology Friends of Cancer Research Parent Project Muscular Dystrophy Andrew...
BioCentury | Jun 28, 2019
Clinical News

Pfizer planning Phase III for DMD gene therapy, close on Sarepta's heels

...race to the finish line between it and Sarepta. Pfizer Inc. (NYSE:PFE) said at the Parent Project Muscular Dystrophy...
BioCentury | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

...published natural history data. FibroGen presented the data on the mAb against CTGF at the Parent Project Muscular Dystrophy...
BioCentury | Dec 20, 2018
Politics & Policy

FDA releases next guidance in patient-focused drug development series

...all stakeholders including patient advocacy groups, some of whom have already submitted guidances to FDA. Parent Project Muscular Dystrophy...
...scientific data to represent patient experiences rather than compiled anecdotes (see "Making Patients Partners" ). Allison Johnson FDA Parent Project Muscular Dystrophy Amyloidosis...
BioCentury | Jun 21, 2018
Company News

Sarepta says no to right to try for its DMD therapies

...hope is that it will get approved, and compassionate use won't be necessary," Miller said. Parent Project Muscular Dystrophy...
BioCentury | Feb 24, 2018
Regulation

Herculean task for DMD

...Inc., Summit Therapeutics plc and Wave Life Sciences Ltd. Steering Committee members include CureDuchenne and Parent Project Muscular Dystrophy...
...Calif. Duchenne UK, London, U.K. National Institute for Health and Care Excellence (NICE), London, U.K. Parent Project Muscular Dystrophy...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

...testing 1.1 x 10 14 vg/kg AVXS-101 in SMA type 1 patients. On Jan. 17, Parent Project Muscular Dystrophy...
...Harvard Medical School, Boston, Mass. LogicBio Therapeutics Inc., Cambridge, Mass. Nationwide Children’s Hospital, Columbus, Ohio. Parent Project Muscular Dystrophy...
BioCentury | Jan 4, 2018
Financial News

SomaLogic completes $200M financing round

...meaningful signals about health, disease and aging" (see BioCentury Extra, Jan. 6, 2017) . Mary Romeo iCarbonX Novartis AG Parent Project Muscular Dystrophy SomaLogic...
BioCentury | Dec 23, 2017
Regulation

Prioritizing preferences

...at LUNGevity, told BioCentury after the meeting. Annie Kennedy, SVP for legislation and policy at Parent Project Muscular Dystrophy...
...Brunswick, N.J. Kidney Health Initiative, Washington, D.C. LUNGevity, Chicago, Ill. Milken Institute, Santa Monica, Calif. Parent Project Muscular Dystrophy...
Items per page:
1 - 10 of 49